STC-004

On May 27, Eli Lilly announced a strategic move to acquire SiteOne Therapeutics in a deal worth up to $1 billion, underscoring its commitment to expanding non-opioid pain therapies. The deal centers on STC-004, a Nav1.8 inhibitor that’s poised to enter Phase 2 clinical trials.   Nav1.8 is an ion channel critical to pain signal transmission in the peripheral nervous system. By targeting this pathway, STC-004 offers hope for long-term relief from chronic pain without the addiction risks associated with opioids. Lilly will pay $300–400 million upfront, with the remainder tied to regulatory and commercial milestones.   This acquisition strengthens Lilly’s pipeline beyond its current blockbuster drugs like tirzepatide for obesity and diabetes. Notably, Vertex Pharmaceuticals is the only company so far to have secured approval for a NaV1.8 inhibitor (Journavx), after past setbacks in the class.   The path to non-opioid analgesics has been challenging. Vertex halted development of two similar candidates in 2020 before succeeding with one in later trials, though it failed to outperform Vicodin, a traditional opioid.   Lilly has previously ventured into pain treatment, collaborating with Pfizer on tanezumab, a nerve growth factor (NGF) inhibitor. Despite initial promise in treating osteoarthritis, tanezumab was ultimately rejected by regulators over safety concerns.   With the global opioid crisis intensifying, the industry is racing to develop safer, effective alternatives. If STC-004 can continue showing clinical promise, it may become a game-changer for millions suffering from chronic pain.

On May 28, 2025, Eli Lilly announced its acquisition of SiteOne Therapeutics, a privately held biopharmaceutical company, in a deal valued at up to $1 billion. This strategic move grants Eli Lilly access to STC-004, SiteOne’s experimental non-opioid pain treatment targeting Nav1.8 channels involved in pain signal transmission.    The acquisition aligns with Eli Lilly’s broader strategy to diversify its pain management portfolio beyond traditional opioids. STC-004 represents a novel approach, aiming to provide effective pain relief without the addiction risks associated with opioid therapies. This move positions Eli Lilly to further expand its footprint in the non-opioid pain relief market, addressing a significant unmet need in pain management.